Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income - MinorityNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRent ExpenseResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShare-based Compensation (IS)Share-based Compensation (IS)Shares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Avricore Health (AVCRF) Consolidated Net Income (2016 - 2025)

Avricore Health has reported Consolidated Net Income over the past 12 years, most recently at -$321177.9 for Q4 2025.

  • Quarterly Consolidated Net Income fell 585.12% to -$321177.9 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$987641.1 through Dec 2025, down 1137.32% year-over-year, with the annual reading at -$981497.4 for FY2025, 1141.68% down from the prior year.
  • Consolidated Net Income was -$321177.9 for Q4 2025 at Avricore Health, down from -$274846.8 in the prior quarter.
  • Over five years, Consolidated Net Income peaked at $117616.8 in Q1 2024 and troughed at -$339282.8 in Q2 2025.
  • The 5-year median for Consolidated Net Income is -$115280.6 (2024), against an average of -$97291.3.
  • Year-over-year, Consolidated Net Income tumbled 1832.59% in 2022 and then skyrocketed 165.79% in 2023.
  • A 5-year view of Consolidated Net Income shows it stood at -$31751.7 in 2021, then plummeted by 448.54% to -$174171.3 in 2022, then skyrocketed by 129.34% to $51100.9 in 2023, then increased by 29.56% to $66206.0 in 2024, then crashed by 585.12% to -$321177.9 in 2025.
  • Per Business Quant, the three most recent readings for AVCRF's Consolidated Net Income are -$321177.9 (Q4 2025), -$274846.8 (Q3 2025), and -$339282.8 (Q2 2025).